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Abstract 1	
 2	
Voltage-gated ion channels (VGICs) are specialised ion channels that have a voltage dependent 3	
mode of action, where ion conduction, or gating, is controlled by a voltage-sensing mechanism. 4	
VGICs are critical for electrical signalling and are therefore important pharmacological targets. 5	
Among these, voltage-gated sodium channels (NaVs) have attracted particular attention as 6	
potential analgesic targets. NaVs, however, comprise several structurally similar subtypes with 7	
unique localisations and distinct functions, ranging from amplification of action potentials in 8	
nociception (e.g. NaV1.7) to controlling electrical signalling in cardiac function (NaV1.5). 9	
Understanding the structural basis of NaV function is therefore of great significance, both to 10	
our knowledge of electrical signalling and in development of subtype and state selective drugs. 11	
An important tool in this pursuit has been the use of peptides from animal venoms as selective 12	
NaV modulators. In this review, we look at peptides, particularly from spider venoms, that 13	
inhibit NaVs by binding to the voltage sensing domain (VSD) of this channel, known as gating 14	
modifier toxins (GMT). In the first part of the review, we look at the structural determinants of 15	
voltage sensing in VGICs, the gating cycle and the conformational changes that accompany 16	
VSD movement. Next, the modulation of the analgesic target NaV1.7 by GMTs is reviewed to 17	
develop bioinformatic tools that, based on sequence information alone, can identify toxins that 18	
are likely to inhibit this channel. The same approach is also used to define VSD sequences, 19	
other than that from NaV1.7, which are likely to be sensitive to this class of toxins. The final 20	
section of the review focuses on the important role of the cellular membrane in channel 21	
modulation and also how the lipid composition affects measurements of peptide-channel 22	
interactions both in binding kinetics measurements in solution and in cell-based functional 23	
assays.  24	
 25	
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1 Introduction 1	
Voltage-gated ion channels (VGICs), belong to a superfamily of signalling proteins and are 2	
present in all living cells [1]. Isoforms of these VGICs are also known to be expressed in 3	
metastatic cells from a number of cancers [2]. These channels principally function to mediate 4	
conduction of ions across the membrane, and are involved in a wide range of physiological 5	
functions. The VGIC superfamily is encoded by more than 143 genes in the human genome, 6	
making them the third largest family of cell signaling molecules after GPCRs and kinases [1, 7	
3]. The primary role of these ion channels is in communication of electrical signals in the 8	
nervous system, where they are responsible for the generation and transduction of action 9	
potentials. The dysfunction of these VGICs can lead to a multitude of hereditary and congenital 10	
channelopathies including epilepsy, chronic pain, cardiac disorders, autism spectrum disorder, 11	
Schizophrenia and Alzheimer’s disease [4]. Unsurprisingly, these ion channels are also among 12	
the most common drug targets. Despite their ubiquitous involvement in a multitude of disease 13	
states, currently only around 30 ion channel drugs are in the market, targeting less than 10 of 14	
the known ion channel subunits [4]. This means that although ion channels are one of the most 15	
common drug targets, their potential is far from fulfilled. 16	
Perhaps the most intensely pursued VGIC for drug development is NaV1.7, an isoform of the 17	
voltage-gated sodium channel family [5], which compelling genetic evidence has identified as 18	
a promising target for the development of analgesic drugs. The structure of NaVs comprises an 19	
ion-conducting pore surrounded by four voltage-sensing domains (VSDs). The VSDs are 20	
responsible for sensing the polarization of the membrane and will undergo a structural change 21	
when the membrane polarization changes. This conformational change is coupled to the 22	
opening and closing of the channel pore. There is high sequence conservation in the ion-23	
conducting pore of different subtypes of NaVs, while the VSDs of these channels display a 24	
higher sequence divergence [6]. There has, therefore, been a particular focus on identifying 25	
ligands that can modulate channel function through the allosteric, VSD mediated, mechanism 26	
of channel gating [7]. VSD ligands can indirectly serve to stabilize different states of the 27	
channel without binding to the pore. A number of such allosteric, gating modifier, ligands have 28	
been identified with a few in various stages of clinical trials [8, 9].  29	
Although NaV1.7 inhibitors have been pursued intensely for the past decade, there are still 30	
significant gaps in our knowledge regarding the mechanism of voltage sensing [10]. This 31	
knowledge gap is in large part due to the lack of structural data of the channel in its resting 32	
state, which only exists in the presence of a membrane potential or a suitable ligand. A 33	
membrane potential is difficult to establish in the biophysical experiments used to study these 34	
channels in solution. Selective and potent ligands, such as animal venom peptides (toxins), thus 35	
represent not just potential drug leads but also important biophysical tools for the study of 36	
VGICs. In this review, we focus on gating modifiers that stabilize the elusive resting state of 37	
the VSD [11], and use a combination of bioinformatic and kinetic analyses to summarize the 38	
wealth of literature ranging from biophysical to cell-based investigations, with a particular 39	
focus on spider toxins that modulate the gating behavior of NaV1.7. The review is organized 40	
by considering the three components in the channel:ligand complex: (i) the first section 41	
introduces VGICs as a structural class and identifies those that are likely to be involved in 42	
voltage gating. This part also covers the channel architecture and the gating cycle; (ii) in the 43	
second part we look at the structure-activity studies that have been done using venom peptides 44	
that stabilize NaV1.7 in the resting state,  look at the available mutagenesis data from both the 45	
toxin and the channel and use bioinformatics to identify predictors of binding; (iii) in the final 46	
section we look at how the membrane itself can affect the binding kinetics of channel inhibition 47	
by gating modifiers, and we also look at the membrane composition of different cell types and 48	
how this may influence binding measurements. We hope to provide an overview of what has 49	
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been gleaned from a wealth of structural and functional studies and point to some of the 1	
complicating factors that have made capturing the structure of the resting state of the channel 2	
difficult. 3	
 4	
1.1. VGIC architecture  5	
VGICs are integral membrane proteins with diverse structures. The general architecture of 6	
VGICs, however, comprises a pore forming a-subunit comprising 24 transmembrane helices. 7	
The gating and kinetics of the a-subunit may be controlled by auxiliary proteins (e.g. b-8	
subunits in NaVs) [12]. VGICs can either exist as tetramers (e.g. voltage-gated potassium 9	
channels (KVs) or prokaryotic NaVs) or as monomers with four homologous domains (e.g. 10	
eukaryotic NaVs and voltage-gated calcium channels (CaVs)). Tetrameric channels can either 11	
be homomeric or heteromeric. Each domain contains six transmembrane (TM) segments (S1–12	
S6) joined by intra- or extracellular loops. The four domains fold together in a circular 13	
orientation such that domains I and IV are brought into close proximity. The S5-S6 segments 14	
from each of the four domains come together to form a pore domain (PD). The pore domain 15	
comprises a wide outer vestibule on the extracellular side, a selectivity filter (upper gate), a 16	
large water filled central cavity and an intracellular activation gate (lower gate). The 17	
conformational changes in the upper and lower gates control ion conduction. The S1-S4 18	
segment of each domain forms a VSD where the positively-charged S4 segments serve as 19	
voltage sensors that initiate voltage-dependent activation by moving outward under the 20	
influence of changes in membrane potential [13]. This movement controls the opening of the 21	
channel. The VSD of each domain interfaces the PD of the neighbouring domain (Fig. 1).The 22	
channels may have additional extracellular or intracellular domains depending on their specific 23	
functions [12]. 24	
 25	
[Figure 1 near here] 26	
 27	
VGIC are classified in families by the type of ion they conduct and each family typically 28	
contains multiple isoforms or subtypes, each with different signalling properties and tissue 29	
distribution. In humans, voltage gated sodium channels (NaVs) are classified into nine different 30	
subtypes, denoted NaV1.1 to 1.9 [14]. The a-subunit of mammalian NaVs comprise four 31	
internally homologous but non-identical domains (denoted domains I to IV) connected by 32	
intracellular linkers (Fig. 1).  33	
The pore domain (PD) and the VSD only share a small interface and it has been shown that the 34	
structure of the VSD (S1-S4) is unperturbed when studied in isolation [14]. This modular 35	
architecture is consistent with the observation that VSDs occur naturally as domains in 36	
enzymes and can exist without auxiliary domains, as is the case for the proton channel HV1 and 37	
voltage sensing phosphatase [15-17]. Conversely ion-channels exist that only contain the PD 38	
without the VSD [18]. Finally, it has been shown that it is possible to transfer segments of the 39	
VSD from one type of ion-channel to another without loss of ion-selectivity or activity [19]. 40	
Thus, the VSD of VGICs can be regarded as independent structural domains. Much of the 41	
structural characterisation of ion channels have to date been from X-ray structures of 42	
symmetrical homo-tetrameric channels from prokaryotes. However, recent advances in cryo-43	
EM have resulted in the emergence of structures of more complex monomeric channels from 44	
eukaryotes [20].  45	
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The VGICs can be either inhibited by blocking the ion-conducting pore or through modulation 1	
of the VSDs. Here, we are particularly interested in peptides that bind to the less well-conserved 2	
VSD. In the following section, we will discuss VGICs that contain VSDs that are likely to 3	
respond to membrane voltage changes and therefore likely pharmacological targets.  4	
 5	
1.2 Not all voltage-gated ion channels are voltage gated 6	
 7	
VGICs as defined by IUPHAR constitute a diverse structural family of proteins (Table 1) [21]. 8	
The majority of these channels have some voltage sensitivity, but some have VSDs that respond 9	
weakly or not at all to physiological changes in membrane potential. As can be seen in Table 10	
1 some VGICs do not have VSDs and some that do are ligand gated and in the absence of these 11	
ligands may not be voltage sensitive (e.g. TRP channels). Voltage gated sodium (NaVs), 12	
potassium (KVs), calcium (CaVs – including the related CatSper/TP channels) and proton (HVs) 13	
channels contain VSDs that are voltage sensitive in the physiological range and in the absence 14	
of ligands. This voltage sensitivity is mediated by several positive charges in the VSD, typically 15	
in the form of 3 to 6 arginine or lysine residues in the C-terminal transmembrane helix of this 16	
domain (referred to as gating charges). Therefore, the classification in Table 1 appears to be 17	
driven by sequence homology rather than a rational basis of voltage gating.  18	
 19	
[Table 1 near here] 20	
 21	
The focus of this review is the modulation of VGIC function by peptides that modify the 22	
voltage gating behaviour of the channel. In this regard, we are only concerned with VGICs that 23	
have a VSD that can influence the gating behaviour of the channel. Since many of the channels 24	
classified as VGICs do not have voltage sensing VSDs, it is more informative for us to define 25	
a subset of VGICs as “voltage-sensing proteins”, defined as proteins containing a conserved 26	
voltage sensor. This classification has previously been defined by Palovcak et al and applying 27	
the same sequence alignment criteria (HMMER profile) we find a total of 80 known human 28	
genes that are identified as putative voltage-sensing proteins by this tool, including non-ion-29	
channel proteins (Table 2) [22]. These proteins are all predicted to be susceptible to allosteric 30	
regulation through their VSDs.  31	
 32	
[Table 2 near here] 33	
 34	
In Table 2, we observe that only a subset of what are considered VGICs are actually likely to 35	
be voltage sensitive, and there are a number of other proteins not considered VGICs that better 36	
fit into this group. For example, transient receptor potential (Trp) channels have a four-helix 37	
domain that topologically resembles a VSD (Table 1), but this domain is not identified as a 38	
VSD based on the conserved sequence characteristics of a voltage-sensing VSD (based on the 39	
HMMER profile). We also find that even those identified as having the conserved voltage 40	
sensing VSD sequence  [22] do not all contain gating charges (e.g. KCa1.1) and are therefore 41	
likely to be either weakly voltage sensing or not voltage sensing at all. From Table 2, we would 42	
predict that all sequences containing 4 or more gating charges are likely to be susceptible to 43	
allosteric gating by VSD binding ligands, but those containing 3 or less gating charges may or 44	
may not be susceptible to gating modifier ligands. We also note that the 80 sequences in Table 45	
	 6	
2 are from human proteins that have been curated in UniProt. If the entire UniProt database is 1	
probed using the VSD search tool, we find an additional 37 sequences in the human genome 2	
(not shown) that are predicted to contain a VSD, but are yet to be characterised.  3	
 4	
1.3 The VSD in a polarised membrane 5	
The electrical potential across the membrane is generated by differences in the concentration 6	
of different ions on either side of the membrane. The extracellular side has a net positive charge 7	
compared to the intracellular side (or conversely, the intracellular side has a net negative 8	
charge). This inequality is due to pumps that actively transport ions across the cell membrane 9	
against their electrochemical gradient, resulting in an electrical potential difference between 10	
the two sides of the membrane. The hydrocarbon tails of the lipids are weakly polarisable and 11	
effectively act as insulation [7]. Outside the membrane the field can be considered constant and 12	
the movement of charged particles here, will not be affected by the potential difference. 13	
Proteins that span the membrane, however, are polarisable and these will be affected by the 14	
difference in electrical potential between the two sides. Helical proteins additionally have a 15	
natural dipole that runs from the positive N-terminus to the negative C-terminus, which is due 16	
to the polar carbonyl groups aligning perpendicular to the plane of the membrane. Thus, it is 17	
energetically more favourable for a helix that spans a polarised membrane to be oriented such 18	
that its N-terminus is on the intracellular side with the C-terminus on the extracellular side 19	
(compared to the reverse) [23]. In a VSD the S1 and S3 helices are in a favourable alignment 20	
with the C=O groups pointing towards the more positive extracellular environment, while the 21	
S2 and S4 helices are in an unfavourable alignment with the helix dipole pointing in the 22	
opposite direction to the voltage potential across the membrane. This would suggest that there 23	
is a force that would tilt the S2 and S4 helices towards the plane of the membrane (as they 24	
would prefer to ‘flip’), while the S1 and S3 helices would favour to be perpendicular to the 25	
plane of the membrane [24]. In the absence of a membrane potential there would be no 26	
particular force that would interact with the helix dipole, and we propose that this may be 27	
sufficient to make the protein more dynamic (than it is in the presence of a membrane 28	
potential). This proposed plasticity of the depolarised state is consistent with the structural 29	
heterogeneity of VSDs observed in structural studies of VGICs. 30	
The sidechains themselves are also polarisable and their importance is highlighted by the 31	
extensive bioinformatic analysis by Palovcak et al [22], which shows that the following regions 32	
of the VSD are highly conserved:  33	
i. Basic residues separated by 3 amino acids in S4.  34	
ii. One acidic residue in S2, one acidic residue or asparagine in S2 and one acidic residue 35	
in S3.  36	
iii. An aromatic residue between the two acidic residues in S2 and facing a hydrophobic 37	
residue in S1. 38	
In the polarised membrane, many basic residues that line the S4 helix (point i above) will be 39	
attracted to the intracellular anionic side of the membrane, thus exerting a further force (in 40	
addition to the helix dipole) to move inward towards the more negative side of the membrane. 41	
Similar to the argument above regarding the helix dipole, this force would once again be 42	
removed when the membrane becomes depolarised and the S4 helix would shift away from the 43	
intracellular side [25]. The movement of the S4 charges across a hydrophobic membrane would 44	
be energetically very costly, and the presence of the counter charges (see point ii above) 45	
provides a low energy pathway for this movement to occur [13]. The movements of the S4 46	
helix have previously been modelled, where it was shown that arginine residues in the S4 47	
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segment (including those in (i) above) change their interactions with residues in the 1	
intracellular negative charge cluster (INC) to those in the extracellular negative charge cluster 2	
(ENC) – including those residues in (ii) above. It was further shown that a focused electric field 3	
between the extracellular and intracellular side of the membrane was generated by the 4	
hydrophobic constriction site (HCS) that plays a crucial role in the translocation of the gating 5	
charges from the INC to ENC resulting in outward movement of the S4 transmembrane 6	
segment. The modelling further showed that the translocation of the S4 segment generates a 7	
concerted conformational change in the pore domain that allows the intracellular activation 8	
gate to open and conduct ions in the open state [26]. 9	
Combining the effect of the helix dipole with the S4 basic charges, it is likely that the S4 helix 10	
undergoes both a tilt and a shift in response to the change in membrane polarisation. This is 11	
consistent with both the modelling discussed above and EPR studies of the KvAP channel in 12	
solution where the membrane potential was artificially mimicked through protein-lipid 13	
interactions [27]. It should be stressed that all the existing high-resolution structural data is in 14	
the absence of a membrane potential. Thus, models describing the structure of the VSD in the 15	
presence of a membrane potential remain to be confirmed. 16	
Finally, we note that the helices have hydrophobic residues facing the membrane with the lining 17	
of the VSD containing largely polar amino acids.  The presence of these polar residues suggests 18	
that the VSD interior is water accessible with the conserved hydrophobic residues, noted above 19	
in point (iii), near the centre of the VSD providing a hydrophobic division between the extra- 20	
and intra-cellular solution [27]. There are also conserved regions in the N- and C-termini, but 21	
these are likely important for anchoring the protein in the membrane.  22	
 23	
[Figure 2 near here] 24	
 25	
1.4 The gating cycle 26	
In the above section the anatomy of the channel is discussed as well as the mechanics of the 27	
forces that influence movement of the VSD, but how does this relate to the function of the 28	
channel and how do ligands influence this? For many proteins/enzymes the structure of the 29	
protein in solution represents a state that does not change much in response to ligand binding, 30	
and often a ligand can be “docked” onto/into the protein in silico or indeed the ligand can be 31	
experimentally “soaked” into a protein crystal, in both cases pointing to minor conformational 32	
changes required to accommodate the ligand [28, 29]. This type of behaviour has been of great 33	
utility in drug discovery and development. Transmembrane proteins, that often act to transport 34	
signals or cargo across the membrane, are notorious for not conforming to this 35	
pharmaceutically useful behaviour. They can (and very often will) undergo significant 36	
conformational changes in response to a number of factors such as auxiliary proteins, ligands, 37	
membrane composition and membrane polarisation, to name a few. VGICs are an excellent 38	
incarnation of the more complex and dynamic scenario, as the very existence of these signal 39	
transduction proteins relies on relatively large conformational changes that lead to opening and 40	
closing of the ion conducting pore.  41	
It may at this stage seem like we can categorise the structure of the VGICs as either open or 42	
closed. The closed state is preferred in a polarised membrane and is also known as the “resting” 43	
state. In this state, the S4 segment of the VSD would be drawn to the intracellular side by the 44	
gating charges and this state is therefore sometimes also referred to as the “down” state. This 45	
conformation prevents the channel gate from opening. When the membrane is depolarised, the 46	
channel will transition to an open state. There is no longer any force acting on the gating 47	
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charges of the VSD, and it can transition from the down state to a more relaxed “up” state, 1	
allowing the channel gate to open and ions to pass. In reality, there are more than these two 2	
states, as channel opening needs to be fine-tuned such that each channel is only open for a 3	
distinct period of time, and such that prolonged depolarisation does not lead to persistent 4	
currents [30]. To control this, the channel transitions from the open state to an “inactivated” 5	
state – a process referred to as fast inactivation. In this state, the channel is occluded by an 6	
alternative mechanism. In NaVs, this mechanism is controlled by movement of the VSD of 7	
domain IV which moves slower than the VSDs of the other domains in response to 8	
depolarisation. This movements results in occlusion of the pore by an inactivation particle (or 9	
IFM particle) in the intracellular domain III-IV loop. In the inactivated state the channel is thus 10	
in an open, but non-conducting state, and the VSDs are all in the “up” state since the membrane 11	
is depolarised. Once the membrane is repolarised, the channel will transition through a 12	
deactivated state where the channel gate is closed and the channel is inactivated, subsequently 13	
returning back to the resting state [13]. In the simplest terms the gating cycle can be considered 14	
as transitions from the closed state to the open state, and then the inactivated state, through the 15	
deactivated state before finally returning back to the closed state (Figure 3).  16	
 17	
[Figure 3 near here] 18	
 19	
Even this very simple model has multiple conformational states with complex and dynamic 20	
equilibria. In reality, the problem is actually more complicated; the above model for the VGIC 21	
must be expanded with additional conformational states and equilibrium constants to account 22	
for: i) fast vs slow inactivation, ii) auxiliary subunits and iii) membrane composition. The 23	
equilibria are further sensitive to pH, temperature and the concentration of various ions in the 24	
solution. For the channels that have four distinct VSDs (see tables 1 & 2 – note that this includes 25	
heteromeric KVs) the sensitivity of each VSD to the above parameters must also be taken into 26	
account. Although heroic attempts have been made to deconvolute all possible equilibria in 27	
mathematical models, the number of parameters very quickly exceeds what can be controlled 28	
under standard experimental conditions, and it is often easier to simplify the model to the three-29	
state model (closed-open-inactivated), ignoring all augmenting variables [31, 32]. In the 30	
context of this review we will discuss how venom peptides modulate channel function and this 31	
simpler model is nearly always sufficient. In Figure 3, we note particularly that those peptides 32	
that inhibit the channel (and are therefore of particular pharmacological interest) can do this by 33	
either stabilising the resting or inactivated states of the channel. This involves either trapping 34	
the VSD responsible for channel opening in the resting, down, state, or trapping the VSD 35	
responsible for return of the channel to the resting, in the inactivated, up, state – see also section 36	
2.1. In NaV1.7, this corresponds to stabilising the VSD of domain II (VSD-II) in the down state 37	
or stabilising the VSD-IV in the up state. Structural characterisation of the latter has been 38	
achieved in channel chimeras [33] but the former remains a state difficult to access by high 39	
resolution structural studies, and poses a significant hurdle in both understanding the structural 40	
basis of voltage sensing and for rational drug design. Although the VSDs of domains I and III 41	
are also involved in the gating cycle, we will not discuss these further as they are currently not 42	
known to be the sites of any channel inhibitors. 43	
 44	
2. Structure activity studies of VSD-peptide interactions 45	
2.1 Modulation of voltage sensing by venom peptides 46	
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In the previous section, we described the VSD of VGICs and in particular noted the difficulties 1	
in accessing structural information regarding channel inhibition by stabilising the down state 2	
of the VSD. In NaVs this would involve binding to the VSD-DII of the ion channel in the elusive 3	
resting/polarised/down state of the channel. Instead, much of what is known about this route 4	
of channel inhibition has been gleaned by exploring the mechanism of channel inhibition by 5	
venom peptides [10, 34-37]. In this section, we will look at this fascinating class of compounds 6	
and in particular focus on structure-activity studies revealing the details of peptide-channel 7	
interaction involving the resting state of the VSD-DII of NaVs.  8	
A recent survey of all reported venom peptide revealed that there are ~1,000 ion-channel 9	
modulators reported to date [10]. Of these, 407 are NaV channel modulators, 278 are KV 10	
modulators and 98 are CaV channel modulators. Scorpion venoms appear to be a particularly 11	
rich source of VGIC modulators with ~350 reported peptides, followed by spiders with ~200 12	
peptides. This analysis revealed that NaVs have been particularly well represented in studies of 13	
venom peptides. Many peptides from both scorpions and spiders have been found to modulate 14	
these ion channels through interaction with the VSDs. This is in contrast to cone snail venom 15	
peptides that inhibit VGICs by binding to the pore of the channel [38]. Pharmacologically, pore 16	
blockers would act in a similar manner to existing pharmaceuticals such as local anaesthetics 17	
(although their binding sites are not the same). Peptides that modulate the channel through 18	
binding to the VSD, therefore present a novel mechanism of ion-channel modulation. It is in 19	
part due to this unique mode-of-action that venom peptides have attracted great interest from 20	
academia and the pharmaceutical industry alike as a source of VGIC modulators [34, 39].  21	
Nowhere is this interest more evident than the, now more than, decade long search for a 22	
selective peptide inhibitor of NaV1.7. NaV1.7 has attracted attention as a drug target due to a 23	
number of reports in the mid 2000s conclusively linking loss-of-function mutations in this 24	
channel to congenital insensitivity to pain (CIP) in humans [40]. This provides compelling 25	
evidence that inhibition of NaV1.7 would lead to analgesia. The 1.7 subtype is, however, only 26	
one of nine NaV subtypes and inhibition of many of the other subtypes would lead to 27	
unacceptable adverse effects including ataxia and cardiac arrhythmia/arrest, creating a narrow 28	
therapeutic window for poorly selective ligands [38]. Peptides that bind to the VSD of NaV1.7 29	
are considered particularly attractive since this region of the channel is less conserved than the 30	
pore region, and it is hoped that higher selectivity can be achieved by so called gating modifier 31	
toxins (GMTs) that bind to the VSD of VGICs [38, 41].  32	
From the simple model in Figure 3 we see that we can achieve channel inhibition by either 33	
stabilising the closed or inactivated state of the VSD. Binding to the inactivated state requires 34	
that the GMT binds to the channel after the channel has undergone at least one gating cycle, 35	
whereas GMTs that bind to the closed state are more attractive since they bind to the channel 36	
in its resting state and do not require the channel to have undergone a gating cycle. One of the 37	
first and most promising peptides reported that binds to the VSD of NaV1.7 was ProTx-II 38	
isolated from the venom of the tarantula Thrixopelma pruriens [42, 43]. Almost in parallel, 39	
another spider venom peptide, HwTx-IV, was described to also act as a GMT [44, 45].  40	
Both toxins are disulfide rich peptides that fold into the well characterised inhibitor cystine 41	
knot (ICK) motif, although they have low sequence identity beyond their cystine framework. 42	
Nevertheless, both of these peptides were initially found to bind to the VSD-DII of NaV1.7. 43	
Later, however, it was shown that their binding site on VSD-DII of NaV1.7 only partially 44	
overlapped, suggesting that they have slightly different channel recognition motifs [46]. 45	
Furthermore, it was found that ProTx-II in addition to binding to the VSD-DII also binds to the 46	
VSD-DIV of NaV1.7 [46].  47	
	 10	
Using the simple model in Figure 3, binding to VSD-DII in NaVs affects the transition from the 1	
closed state to the open state, effectively trapping the channel in the resting state. Binding to 2	
VSD-DIV has a more complex pharmacology, resulting in two contrasting outcomes. In one 3	
case binding to DIV can affect the transition from the open to the inactivated state, which would 4	
lead to unwanted persistent currents and may indeed be the desired pharmacological outcome 5	
from the venomous creature’s point of view [47]. On the other hand, binding to DIV may also 6	
impede the transition from the inactivated state to the resting state, thus not allowing the 7	
channel to respond to subsequent depolarisation. The second scenario also leads to channel 8	
inhibition, and has been shown to be the mechanism by which recently developed sulfonamide 9	
ligands inhibit the channel [33].  10	
Interestingly, these two distinct pharmacological outcomes suggest that the VSD has a different 11	
conformation in the open and the inactivated state (i.e. two distinct ‘up’ states), both in the 12	
absence of membrane polarisation. Indeed, recent work in characterising the binding of another 13	
spider venom peptide, VSTx1, to the VSD of the archeal KV channel KvAP have provided 14	
evidence that the VSD is dynamic and sensitive to the binding of the toxin [48-50].  15	
 16	
2.2 HwTx-IV sensitive VSDs 17	
Structural details of the down state of NaVs remain speculative and even more so in the presence 18	
of a peptide ligand. There is, however, detailed mutagenesis work which has revealed the amino 19	
acids in these channels that make them sensitive to HwTx-IV [37]. In this section, we will look 20	
at these structure-activity-relationship (SAR) studies and use the information from these in 21	
combination with sequence alignments to predict more broadly what VGIC VSDs are likely to 22	
be sensitive to toxins such as HwTx-IV. This information will inform what channels will be 23	
important to counter-screen against when developing selective VSD-DII ligands that have a 24	
similar binding mode to HwTx-IV. 25	
The comprehensive mutagenesis work by the Cummins group showed that five residues of 26	
NaV1.7-VSD-II were particularly important for peptide biding – E753, E811, L814, D816 and 27	
E818 (EELDE). The first of these is in the S1-S2 region of the channel, while the other four 28	
are in the S3-S4 region, placing the toxin inside the cavity formed between the four helices of 29	
the VSD (note that none of these correspond to the conserved residues shown in Figure 2). This 30	
mode of binding is also consistent with recent solution state and mutagenesis studies of other 31	
related systems [36, 48]. Given that we have in Table 2 generated a list of all VSDs aligned 32	
according to their shared structural homology, and we know what residues are determinants for 33	
HwTx-IV sensitivity, it is in principle now possible to query what VSDs are likely to bind the 34	
toxin.  If we classify all the VSDs in Table 2 based on how many of the EELDE motif they 35	
have (allowing D to E mutations and L to A/I/V mutations), and we apply a strict filter requiring 36	
the final acidic residue (as shown by previous studies to be required) we arrive at the data 37	
summarised in Table 3. We can then rank likely HwTx-IV sensitive VSDs based on how many 38	
of the required residues they contain. 39	
 40	
[Table 3 near here] 41	
 42	
The data in Table 3 is notable because the subtype selectivity of HwTx-IV for NaVs is well 43	
characterised and it is known to bind 1.7, 1.6, 1.1, 1.2 and 1.3 channels only [51], as predicted 44	
from the above table. The activity of the toxin on CaV1.3 has not been described in the literature 45	
	 11	
to the best knowledge of the authors, but our analysis suggests that the peptide will bind 1	
strongly to this channel as well as several of the CaV3 subtypes.  2	
 3	
2.3 NaV1.7-DII binding peptides 4	
The analysis done in the above section relies on detailed mutagenesis of the VSD with 5	
corresponding activity data as well as a good alignment template. HwTx-IV is itself extremely 6	
well characterised in terms of mutagenesis studies mapping the residues required for the 7	
activity of the toxin against NaV1.7. Similarly, alignments of the ICK fold have been described 8	
in detail and alignment templates have been generated [34, 35, 52]. Thus, it is possible to apply 9	
a similar analysis as above to identify toxins that are likely to act as inhibitors of NaV1.7. 10	
Residues K31/W29 are absolutely required for activity of HwTx-IV. S24 is required to position 11	
K31/W29 correctly, and a hydrophobic residue in either position 7 or 8 is important for 12	
membrane association and may be important for VSD binding as well [53]. This provides us 13	
with X1X2SWCKX3 motif that is essential for the activity of the peptide on NaV1.7. The K and 14	
W residues are known to be essential for the activity of the peptide while the other residues all 15	
have additive effects on the activity. Allowing for any hydrophobic residue (I, L, V, M, F, W 16	
or Y) in place of X and removing those that lack the KCW motif results in a list of potential 17	
NaV1.7 inhibitors (Table 4).  18	
 19	
[Table 4 near here.] 20	
 21	
In Table 4 we find, as expected, that HwTx-IV (Hs2a) has all the critical residues (7), but we 22	
also find that Hhn2b has 5 of the 7 required residues. Hhn2b is known to be inactive on NaV1.7 23	
and indeed the two missing residues (X2 and S) were shown to each contribute independently 24	
to the lack of activity. If either of the two residues (G and N) is mutated into the corresponding 25	
required residues, the peptide regains activity (albeit with a lower potency), and if both are 26	
mutated to the corresponding required residues, the protein has a similar potency to HwTx-IV 27	
[53]. Thus, although our analysis would suggest that all of the toxins with 7 recognition 28	
residues should inhibit NaV1.7, and those with 6 residues should all produce activity but 29	
perhaps with some reduced potency, we note that those with 5 may or may not inhibit NaV1.7 30	
depending on how additive the effect of the missing residues are.  31	
Nevertheless, the training of a sequence alignment tool and the subsequent sequence analysis 32	
complemented with information from detailed mutagenesis yields a remarkable result in that 33	
most of the peptides in Table 4 are known inhibitors of NaVs. This would allow future 34	
transcriptomic and proteomic data be processed using these tools to identify potential NaV1.7 35	
inhibitors that act with a similar mechanism of action as HwTx-IV. Interestingly HwTx-I 36	
(Hs1a) and Gr2a were initially identified as calcium channel inhibitors and later also found to 37	
inhibit sodium channels. If we combine the information from Tables 3 and 4 we may conclude 38	
that many of the peptides in Table 4 are likely to bind to the VSDs of the top hits in Table 3, 39	
which are primarily NaVs and CaVs.  40	
 41	
2.4 In silico screening of venoms 42	
The above analysis to identify peptide sensitive VSDs and VSD binding peptides raises the 43	
question of whether future screening efforts can be conducted in silico. It should be noted that 44	
the bioinformatic analysis performed here is only possible due to the availability of a wealth of 45	
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functional data from detailed mutagenesis data. Thus, the analysis is only applicable to known 1	
and well characterised families of ligands and receptors.  2	
The argument can be made that such in silico analysis will simply identify variants of known 3	
inhibitors. The counter argument is that it is exceptionally rare to find a completely new class 4	
of peptides that target a well-established receptor via a novel mechanism. For example, despite 5	
extensive screening of venoms for NaV1.7 inhibitors, all reported inhibitors fall within either 6	
the HwTx-IV family or the ProTx-II families (the reported centipede toxin is excluded as its 7	
NaV inhibition cannot be confirmed independently [54]). This includes a recent screen of 205 8	
venoms where all the characterised and reported hits fell within the sequence space that would 9	
have been identified by the analysis in section 2.3 [39]. It would, therefore, appear that for new 10	
targets, there would be significant value in initial screening of venoms to identify consistent 11	
hits. Once these are identified, however, the effort should be focused on establishing detailed 12	
SAR data through careful mutagenesis.  13	
The benefit of performing in silico screening of venoms for a known and well characterised 14	
ligand-target pair is that the wealth of sequence data provides a database of sequence variants 15	
that have been optimised by evolution and are likely to be stable and soluble. In contrast, simple 16	
alanine or arginine scanning, can often lead to insoluble or misfolded peptides. The natural 17	
sequence variation will also point to regions that are tolerant to mutations, insertions and 18	
deletions – information that is otherwise very difficult to acquire. In the case of finding a 19	
NaV1.7 inhibitor that has the desired analgesic effect, the inhibitor is required to be VGIC and 20	
subtype selective. The natural sequence variants identified through analysis of transcriptomic 21	
data provides an ideal starting point for addressing this. Thus, although in silico screening will 22	
not identify new classes of molecules, it provides an excellent tool in the optimisation process 23	
of known ligand classes. 24	
An example of the sequence diversity apparent from our analysis is that the first of the 7 25	
residues in Table 4 is uniquely a proline in P0CH54. This may have a significant effect on the 26	
structure of the first loop in the peptide and would be an interesting mutation to explore. 27	
Similarly, the sequence alignment of the sequences in Table 4 (not shown) reveals a highly 28	
conserved proline residue which is placed two residues after the second cysteine, however, in 29	
both P0CH54 and B1P1H2 this residue is a tyrosine. These are only a few observation and 30	
further natural sequence variations are apparent in different positions, that would otherwise be 31	
difficult to arrive at by existing mutagenesis approaches.  32	
 33	
3. Binding kinetics in the presence of a lipid bilayer 34	
3.1 Binding kinetics of spider toxin gating modifiers 35	
In the previous sections, we have discussed in some detail the SAR studies that underpin our 36	
understanding of channel inhibition by GMTs. However, many of the determinants of toxin 37	
activity may not just purely involve protein-protein interactions. This is evident in studies 38	
showing that toxin activity cannot be fully explained by channel:peptide binding kinetics in the 39	
absence of a lipid bilayer [55]. The lipid bilayer, thus, plays a significant role in toxin binding 40	
and many of the GMTs described to date have also been shown to bind to lipid bilayers [53, 41	
55, 56]. Further, the lipid bilayer composition has been shown to modulate the gating 42	
mechanism of the channel [57, 58]. In this section, we will first briefly review the literature on 43	
lipid binding of GMTs and in the subsequent two sections discuss the impact of the lipid bilayer 44	
on the binding kinetics of GMTs (3.2) and then review the lipid composition of cells that are 45	
both the target of GMTs and those commonly used in functional assays (3.3). 46	
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One of the earliest reports on the effects of the lipid bilayer on binding kinetics of GMTs was 1	
from the MacKinnon group, where they describe the interaction of a GMT (VSTx1) with a 2	
voltage gated potassium channel (KvAP) as well as its high affinity for lipid like micelles and 3	
bilayers [55]. Similarly, GMTs such as hanatoxin [59, 60], ProTx-II [61], HHN2B-G7W [53] 4	
and SGTx [62] have been shown to bind to lipid bilayers. These and several other studies have 5	
also consistently shown that these cationic GMTs have an increased affinity for anionic lipids 6	
[48, 55, 63, 64]. The distribution of the basic residues on the GMTs forms a basic patch 7	
surrounded by hydrophobic residues creating an amphipathic structure which has been 8	
suggested to mediates membrane association by several biophysical studies as well as 9	
molecular dynamics simulations [48, 64-66].  10	
There is therefore a wealth of evidence, suggesting that lipid binding plays an important role 11	
in the pharmacology of GMTs. The exact mechanism, however, is still under some debate. 12	
Some of the different mechanism considered are that (i) the GMTs affinity for the lipid bilayer 13	
has a concentrating effect, localising the peptide near the channel, (ii) individual lipid 14	
molecules that are associated strongly with the channel form part of the channel-toxin complex 15	
in a “trimolecular complex”, or (iii) the peptide partitions into the bilayer followed by lateral 16	
diffusion in the membrane followed by binding to a primarily lipid accessible binding site 17	
(“membrane-access” mechanism) [7, 55]. In the absence of high resolution structural data of a 18	
VSD-GMT complex, the contributions of mechanisms (ii) and (iii) are difficult to quantitate. 19	
In contrast, mechanism (i) makes no assumptions about specific intermolecular interactions 20	
and can be quantitated by classical kinetic models as described below. 21	
 22	
3.2 ‘Membrane catalysis’ as a kinetic model for contribution of lipid binding in channel 23	
inhibition 24	
Lipid partitioning of ligands leading to a ‘concentrating effect’ is well known and models to 25	
account for this have been proposed, with the concept of ‘membrane catalysis’ introduced by 26	
Sargent and Schwyzer [67]. There is now growing evidence to support this phenomenon in 27	
various ligand-receptor systems [68-70]. The model has also been discussed and refined in 28	
various reviews and can be summarised in 3 steps: (i) accumulation of the ligand to the 29	
membrane surface by favourable electrostatic interactions, (ii) partial or complete entry into 30	
the membrane through hydrophobic interactions and (iii) ligand-receptor interactions. 31	
Based on the membrane catalysis model, we can build a simple and practical model to draw 32	
some very general conclusions regarding GMT-VSD interactions. In this model, the local 33	
bilayer is considered as an independent entity in the three-component system (ligand, receptor 34	
and membrane). In the simplest case when not considering the effect of the membrane, the 35	
equilibrium between the GMT and the VSD follows a 1:1 non-competitive binding mode: 36	
Lf  +   Rf   
𝑘"#⇌𝑘"%%   RL   (1)  37	 	𝐾( = 	)*++	)*,   = [.]+[0]+.0   (2) 38	
where L is the ligand (i.e. the GMT), R is the receptor (i.e. the VSD), [R]f is the concentration 39	
of the free R, [L]f is the concentration of the free L, [RL] is the complex concentration and the 40	
equilibrium dissociation constant, 	𝐾1 , is the ratio of the association constant, 	𝑘"#  and 41	
dissociation constant, 	𝑘"%%.  42	
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The local ligand concentration near the membrane, and thus the receptor, can be significantly 1	
increased due to (i) electrostatic and/or (ii) hydrophobic interactions. These interactions can 2	
stabilize the ligand to a membrane upon binding,  lowering the ligand 	𝑘"%%. This leads to an 3	
increased or ‘accumulated’ population of ligands near the local bilayer and receptors (i.e. 4	
partitioning). Ligands accumulated due to (i) and (ii) can be defined as having a distinct 5	
concentration in the bilayer compartment, higher than that of the bulk aqueous volume, 𝐿 %. 6	
If we approximate processes (i) and (ii) as mechanisms of concentrating the ligand, then we 7	
can describe them as a combined partitioning equilibrium referred to as 𝐾3. The 𝐾3 is defined 8	
by the ratio of partitioned ligand concentration (in moles per membrane compartment 9	
volume, 𝐿 4), over ligand concentration in the bulk solution (in moles per solution volume, 10	 𝐿 %): 11	 𝐾3 =  [0]50 +   (3) 12	
The 𝐾3 is essentially a multiplicative factor of total ligand concentration, therefore reflecting a 13	
concentrating effect [71]. Note that the model does not implicitly make any assumptions about 14	
the location of the binding site of the channel or the GMT with respect to the bilayer, and in 15	
the GMT-VSD case there is not enough experimental evidence to make any assertions about 16	
this. Furthermore, we cannot make any assumptions regarding the role of the membrane in 17	
preconfiguring the conformation or orientation of the peptide with respect to channel binding 18	
(a slight departure from the membrane catalysis model). Finally, we have here taken a very 19	
generous view of what the membrane compartment volume is. It is, here, considered to extend 20	
as far as favourable electrostatic contributions can exist between any sidechains of the peptide 21	
and the outer membrane leaflet (including associated ions). Thus, a hydrophilic peptide can 22	
still accumulate near the bilayer surface through electrostatic interactions alone.  23	
 24	
[ Figure 4 near here] 25	
 26	
Many GMTs have 𝐾3 values in the range of ~106 and can thus significantly affect binding 27	
kinetics. To account for the contributions of 𝐾3 to the simple model presented by equations 1 28	
and 2, we use the membrane catalysis model to break down the binding event into two separate 29	
steady-state equilibria: 30	
Lf +   Bilayer   67⇌   𝐿4  +   Rf   689⇌      RL   +   Bilayer (5) 31	
 32	
According to this model we assume that the concentration of free ligand ( 𝐿 % ) will be 33	
insignificant compared to partitioned ligands ( 𝐿 4) and the interaction of free ligands with the 34	
receptor can be neglected. Therefore, the 𝐾3  and 𝐾(′contribute to an observed equilibrium 35	
dissociation constant (	𝐾((<33)): 36	 	𝐾((<33) = 689	67         (6) 37	 𝐾(()<33 is a useful representation of binding kinetics for a lipophilic ligand that accounts for 38	
separate 𝐾3 and 𝐾( equilibria. Each of these separate equilibria can in theory be determined 39	
individually by in vitro experiments in solution. Assuming that GMT binding to the VSD leads 40	
to complete channel inhibition as measured by ion conduction, 	𝐾((<33) can  be correlated to 41	 𝐼𝐶@A values from electrophysiology experiments: 42	
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[𝐼𝐶@A] ∝ 	𝐾(()<33        (7) 1	
We stress that this correlation provides only a rough estimate and that these values will further 2	
be modulated depending on the population of different states of the channel the affinity of the 3	
ligand to these states and their effect on the observed ion conduction. Furthermore, we note 4	
that VGICs have four VSDs and in the above we assume that binding to one VSD is adequate 5	
for total modulation of a channel, and suitable modifications may be necessary to account for 6	
stoichiometry when the above is not true. The above models have been applied to the binding 7	
of VSTx1 to KvAP [55]. Electrophysiology experiments performed using KvAP in artificial 8	
bilayers of 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) and 1-Palmitoyl-9	
2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (POPG) composition yielded an 𝐼𝐶@A  of 10	
~10 nM [55, 72, 73]. Further, 𝐾3  values for the partitioning of VSTx1 in bilayers of 1-11	
Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and POPG in liposomes have been 12	
determined with values around 104 reported [48, 55, 63, 65].  13	
Assuming that	𝐾((<33) will be within a few orders of magnitude of the 𝐼𝐶@A we can use 𝐾3 to 14	
estimate the value of 𝐾(′ , and find this to be ~100 µM. This value would represent the 15	
equilibrium dissociation constant between the lipid partitioned ligand and the lipid embedded 16	
receptor. Remarkably, however, the value is in good agreement with equilibrium dissociation 17	
constants measured between micelle embedded receptors and free ligands [48, 55, 64].  18	
Considering the differences in the models used to derive these values, and the incomplete 19	
understanding of the structure of the ligand-receptor complex, it is difficult to draw any firm 20	
conclusions from this, other than to note that lipid partitioning of these ligands will have a 21	
significant effect on 	𝐾((<33) and 𝐼𝐶@Aand that accurate measurements of 𝐾3in an appropriate 22	
lipid model will be important in interpreting functional results. In measurements of 𝐾3 in such 23	
studies, it is imperative that the same lipid composition is maintained for both the cell-based 24	
functional assay and the 𝐾3  measurement in solution (see also 3.3 on cell dependent lipid 25	
compositions). For example, in studies of dihydropyridines, a calcium channel antagonist, [74, 26	
75] and dopmaine receptor antagonists [76] the 𝐾3 was significantly affected by the cholesterol 27	
content and phase of the membrane (liquid crystalline vs gel state).  28	
Currently, 𝐾3  values are derived using artificial membranes composed of purified lipids, 29	
assembled into large unilamellar vescicles (LUVs), where peptide binding is quantitated using 30	
a combination of sedimentation, chromatographic and fluorescence based techniques [71]. 31	
There are two disadvantages with this approach, first the lipid bilayer will not have the same 32	
composition as that used functional assays, and second, the sedimentation and fluorescence 33	
will favour lipid insertion over weak electrostatic interactions that may also lead to membrane 34	
accumulation. An approach that may address some of these problems is the use of lipid 35	
nanodiscs [77-79]. These are disc shaped soluble particles consisting of a flat lipid bilayer 36	
enclosed by a membrane scaffolding protein (MSP). Thus, lipid extracts from cells can be 37	
directly assembled into the nanodiscs and these can be used in more sensitive and higher 38	
resolution biophysical assays such as nuclear magnetic resonance (NMR) and surface plasmon 39	
resonance (SPR) experiments. Although we note that any interaction between the ligand and 40	
the MSP itself must be controlled for carefully. The former is of particular interest as the use 41	
of isotope labelling allows for both structural and functional studies. There have been 42	
significant developments in application of multidimensional NMR experiments to venom 43	
peptides as well as structural studies of membrane proteins in nanodiscs [78, 80, 81]. A 44	
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combination of these technologies is likely to provide new insights into the mechanism of 1	
membrane binding of GMTs.  2	
 3	
3.3 Lipid composition 4	
In the preceding sections, we found that membrane association is a significant component of 5	
the apparent affinity of many VGIC ligands. We also know that the association is highly 6	
dependent on the exact lipid composition. In this section, we will briefly describe both the 7	
lipids themselves and their composition in relevant cell types. This is particularly important in 8	
the development of biophysical assays of lipid binding (𝐾3) that would be relevant to correlate 9	
to functional data (𝐼𝐶@A), as discussed before, but also for interpretation of emerging structural 10	
data. 11	
Lipids make up the bulk of the cellular membrane. The three main types of lipids are 12	
phospholipids, glycolipids, and cholesterol, with phospholipids being the major component of 13	
the membrane. Phospholipids derived from glycerol are called phosphoglycerides (Fig. 5A) 14	
while those from sphingosine are called sphingomyelins or glycolipids (Fig. 5B). Glycolipids 15	
differ from sphingomyelin in the moiety that is attached to the primary OH group of the 16	
sphingomyelin backbone: one or more sugars in glycolipids versus phosphoryl choline in 17	
sphingomyelin (c.f. Fig. 5B). Cholesterol differs from all these lipids in that it is a steroid type 18	
lipid (Fig. 5C). Cholesterol is absent in prokaryote cells whereas it can be present at a very high 19	
concentration in animal membrane [82]. 20	
[Figure 5 near here] 21	
The composition of the cell membranes is dependent on a number of factors including the cell 22	
type. Considering that different cell types are used in VGICs functional assays it is important 23	
to consider what the lipid composition is in the membrane of these cells.  The majority of VGIC 24	
cell-based assays either use channels that are transfected into immortalised cells or neuronal 25	
cells that are selected for overexpression of a particular ion channel and then immortalised. The 26	
primary cell types used in functional assays are mammalian neuronal cells, HEK cells and CHO 27	
cells as well as amphibian oocytes. In Table 5 we have provided an overview of the major lipid 28	
content of these cell types. A wealth of other lipids is present but each constituting < 5% of the 29	
total lipid content and therefore unlikely to contribute significantly to the 𝐾3 of GMTs and are 30	
therefore excluded. It should be noted that the data presented is from different sources 31	
(sometimes using different methods) and should be considered a very crude generalisation. 32	
What should also be considered is that the lipid composition of a cells will be different 33	
dependent on the metabolism of the cell (affected by the growth media and conditions as well 34	
as the point in the cell cycle) and finally, it may be that the VGICs are associated in multiprotein 35	
complexes in lipid rafts that themselves may have very different lipid composition compared 36	
to the rest of the plasma membrane. Nevertheless, the table points to a general composition of 37	
~50-60% of PC/PE lipids 30-40% cholesterol and about 5% each of sphingomyelin (SM), 38	
phosphatidylserine (PS) and phosphatidylinositol (PI) lipids. Of these PS is of particular 39	
interest as it is anionic and would in a similar manner to PG attract the cationic peptides, 40	
however, PS is enriched in the inner leaflet of the membrane and is therefore not likely to have 41	
a significant effect on peptide activity [83]. Similarly, PI is largely found on the inner leaflet 42	
and is unlikely to make a have a significant contribution to peptide binding [83].  In contrast 43	
SM is enriched in the outer membrane and may be present in a higher abundance than indicated 44	
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by Table 5 in the relevant region of the cell membrane for GMT binding. Thus, a model 1	
membrane containing 60% POPC, 30% cholesterol and 10% SM would appear to be reasonable 2	
membrane composition for measurement of 𝐾3 values for GMTs, for comparison with data 3	
from cell-based assays.  4	
[Table 5 near here] 5	
Much of the VGIC structural data to date has been from prokaryotes, first from archea and later 6	
from bacterial sources, each with their own unique lipids. The membranes of archaea are 7	
distinguished from those of eukaryote or bacteria in several ways. First, the two nonpolar 8	
chains (alkyl chains) are joined to the glycerol backbone through an ether bond instead of an 9	
ester bond (the dashed rectangle in Fig. 6) – making it less polar. Second, the alkyl chains are 10	
branched with methyl groups rather than being linear (the dashed ellipsoid in Fig. 6) – making 11	
these more hydrophobic and potentially affecting the lipid order. Third, the glycerol backbone 12	
is a stereoisomer of that in phosphatides (Figs 5A and 6) – providing a different chirality [84], 13	
and finally, the phosphate headgroups are decorated with different sugar moieties. Thus, studies 14	
of archeal bacterial channels such as KvAP in POPC and POPG (prevalent in bacteria) is likely 15	
to have consequences for the equilibrium population of the different states of the channel in 16	
the presence and absence of membrane voltage. An interesting observation is that VSTx1, a 17	
peptide that binds to the inactivated state of KvAP in POPE/POPG mixtures is also a weak 18	
inhibitor of NaV channels [85], most likely by binding to the down state of these channels (it 19	
contains 6 of the 7 conserved residues in the HwTx-IV family of peptides as shown in Table 20	
4). This would suggest that the up state of the VSD of KvAP in a POPE/POPG mix shares 21	
structural homology to the down state of NaV channels and the mechanism of voltage gating of 22	
KV channels in archea may indeed be rather different to that observed in mammalian cells 23	
considering the divergent lipid composition of the lipid bilayer as well as the significant 24	
structural changes involving loop sizes and the helix break in KvAP [86].  25	
[Figure 6 near here] 26	
 27	
4. Concluding remarks 28	
VGICs are important pharmacological targets. The allosteric modulation of these channels 29	
through their VSDs presents an opportunity for development of state and subtype selective 30	
modulators. In principle, this mode of channel modulation would address many neurological 31	
disorders but remains largely unexplored. To date, the most abundant source of gating 32	
modifiers has come from peptide toxins from animal venoms. In this review, we have shown 33	
that with detailed knowledge of the VSD architecture and careful structure-activity data it is 34	
possible to use bioinformatic tools to analyse complex sequence data to generate novel peptide 35	
screening tools and identify potential off-targets. This bioinformatic screening approach is very 36	
attractive in the context of the wealth of sequence information that is being generated but also 37	
hinges on availability of high quality experimental data, further highlighting the need for efforts 38	
to characterise the structural mechanism of channel function and inhibition. Such studies are 39	
hampered by the integral role of the membrane in channel inhibition by gating modifiers. 40	
However, recent advances in development of membrane mimetics such as nanodiscs combined 41	
with biophysical characterisation by NMR and cryo-EM promises to lead to new advances in 42	
our understanding of VGICs and ultimately in realising the great potential of this class of 43	
molecules as pharmacological targets. 44	
 45	
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Tables 1	
Table 1. Proteins identified as being part of the voltage-gated ion channel family by the 2	
International Union of Basic & Clinical Pharmacology (IUPHAR) [21].  3	
 Transmembrane 
(TM) segments 
[TMs per subunit] 
Voltage 
sensor 
domain? 
Ligand gated Voltage 
sensing 
protein? 
NaV 24 [24] Yes No Y 
KV 24 [6] Yes No Y 
CaV 24 [24] Yes No Y 
CatSper 24 [6] Yes No Y 
TP-channels 24 [12] Yes No (sensitive to PIP3,5) Y 
HV channels 8 [4] Yes No (highly pH sensitive) Y 
CNG/HCN 24 [6] Yes Yes (cGMP/cAMP) Y 
KCa 24 [6] Yes Yes (Ca2+) N 
TRP channels 24 [24] Yes Yes (various) N 
K2P 8 [4] No Yes (neurotransmitters) N 
Kir 8 [2] No Yes (PIP2) N 
 4	
  5	
	 25	
Table 2. Putative voltage-sensing human proteins identified based on sequence alignment 1	
templated of Palovcak et al. [22]. These are proteins identified as having a voltage sensor 2	
domain (VSD) and are here further classified based on the number of gating charges in their 3	
VSDs. Where channels have more than one VSD, the VSD with the largest number of gating 4	
charges is used. Channels having a VSD with ≥ 4 gating charges are given in standard font in 5	
black. Channels with VSDs containing 3 gating charges are shown in green with italic font, 6	
those containing 2 gating charges are shown in orange and bold font and those containing no 7	
gating charges are shown in red with bold and italic font. 8	
 9	
CatSper CaV HCN/CNG KV NaV Other 
Catsper1 CaV1.1 HCN1 KV1.1 KV4.1 KV8.1 NaV1.1 Nax 
Catsper2 CaV1.2 HCN2 KV1.2 KV4.2 KV8.2 NaV1.2 HV1 
Catsper3 CaV1.3 HCN3 KV1.3 KV4.3 KV9.1 NaV1.3 TM266 
Catsper4 CaV1.4 HCN4 KV1.4 KV5.1 KV9.2 NaV1.4 NalCN 
 CaV2.1 CNG4 KV1.5 KV6.1 KV9.3 NaV1.5 TPTE 
 CaV2.2  KV1.6 KV6.2 KV10.1 NaV1.6 TPTE2 
 CaV2.3  KV1.7 KV6.3 KV10.2 NaV1.7 KCa5 
 CaV3.1  KV1.8 KV6.4 KV11.1 NaV1.8 NHE11 
 CaV3.2  KV2.1 KV7.1 KV11.2 NaV1.9 TPC1 
 CaV3.3  KV2.2 KV7.2 KV11.3  TPC2 
   KV3.1 KV7.3 KV12.1  PKD2L1 
   KV3.2 KV7.4 KV12.2  KCa1.1 
   KV3.3 KV7.5 KV12.3   
   KV3.4     
 10	
 11	
  12	
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Table 3. Human VGICs are shown with VSDs that contain conserved residues that confer 1	
sensitive to HwTx-IV (aligned based on the described HMMER profile). Five residues were 2	
shown to be important for HwTx-IV binding to the VSD of NaVs. The conservation of these 3	
residues in other channels is shown below. Those in bold have all of the required residues and 4	
are most likely to be sensitive to HwTx-IV (indeed both NaV1.7 and NaV1.6 have been shown 5	
to be inhibited potently by this toxin). The alignment is available in the supplemental material 6	
section (Figure S1). 7	
 8	
VGIC Sequence # Required 
residues 
VGIC Sequence # Required 
residues 
NaV1.7 EELDE 5 KV1.1 ETTIE 2 
NaV1.6 EELDE 5 KV1.2 ETTLE 2 
CaV1.3 EELEE 5 Kv1.3 ETTLE 2 
NaV1.1 EELNE 4 KV1.5 ETTLE 2 
NaV1.2 EELNE 4 KV4.3 EGMNE 2 
NaV1.3 EELNE 4 KV9.3 HTVTE 2 
CaV1.1 QDLED 4 NALCN NSLVE 2 
CaV3.1 EGLEE 4 Nav NAX ESGTE 2 
CaV3.2 EGLEE 4 KV10.1 NIFND 1 
CaV3.3 EGLEE 4 KV10.2 NI-AE 1 
Nav1.9 ESITE 3 KV11.1 SLGGE 1 
KV4.1 EGVKD 3 KV11.3 SLGGD 1 
KV4.2 EGMDE 3    
HCN3 GIVEE 3    
TPTE2 DDYFD 3    
TPTE DVVFD 3    
      
 9	
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Table 4. Toxins predicted by our gating modifier HMMER profile to bind to the voltage-sensing 1	
domain (VSD) of NaV1.7. The Uniprot ID of each hit is reported as well as the number of 2	
required residues and the sequence of these residues - footnotes are provided for information 3	
available in UniProt regarding off-targets. The alignment is available in the supplemental 4	
material section (Figure S2). 5	
 6	
Toxin Uniprot ID # Required 
residues 
Sequence 
Mu-theraphotoxin-Hs2a P83303 7 IFSWCKY 
Mu/omega-theraphotoxin-Hs1a P56676 7 VFSWCKW 
Beta/kappa-theraphotoxin-Hlv1a B3EWN3a 7 LFSWCKY 
Beta-theraphotoxin-Ps1a P84510 7 FLSWCKY 
Omega-theraphotoxin-Gr2a P0DJA9 7 FMSWCKY 
Beta-theraphotoxin-Cm1a P84507b 7 WFSWCKY 
Beta-theraphotoxin-Cm1b P84508b 7 WFSWCKY 
Mu-theraphotoxin-Hhn1a P60975 6 FGSWCKY 
Beta-theraphotoxin-Hlv1a B3EWN2 6 FGSWCKY 
Kappa-theraphotoxin-Tb1a P83745c 6 MFNWCKY 
Mu-theraphotoxin-Hhn2a D2Y2D1 6 FGSWCKV 
Kappa-theraphotoxin-Tb1c P83747c 6 MFRWCKY 
Kappa-theraphotoxin-Tb1b P83746c 6 MFRWCKY 
Beta-theraphotoxin-Pmr1a B3EWN0 6 MFNWCKY 
Kappa-theraphotoxin-Gr4a P0C2P5d 6 WFNWCKY 
Jingzhaotoxin F7 P0CH54 6 PFSWCKY 
U24-theraphotoxin-Cg1a B1P1H2 6 LFEWCKI 
Kappa-sparatoxin-Hv1d P61792e 6 LFRWCKY 
Kappa-sparatoxin-Hv1e P61791e 6 LFHWCKY 
Mu-theraphotoxin-Hhn2b D2Y1X6 5 FGNWCKV 
Mu-theraphotoxin-Tp1a P0DL64f 5 FGGWCKL 
a. Blocks human (IC50=80 nM) and rat (IC50=160 nM) NaV1.3, partially inhibits 
human KV11.1/KCNH2/ERG (25% at 175 µM), has no effect on human or rat NaV1.8. 
b. Inhibits CaV2.2 but does not inhibit CaV1.3 or CaV3.1. 
c. Blocks KV4.2 channels (Tb1a: IC50 is 193.0 nM); Tb1b is a low affinity blocker of 
KV4.2. 
d. Weakly inhibits KVAP. 
e. Inhibitor of the KV4/KCND family, also blocks calcium channels (CaVs). 
f. Affects neither human CaVs nor nicotinic acetylcholine receptors (nAChR) at 5 µM. 
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Table 5. Estimates of relative abundance of the major lipid components of four cell types 1	
typically used in functional assays of voltage-gated ion channels. The values in the table are 2	
normalised assuming they only contain these major components and are given in weight 3	
percent unless otherwise indicated. Data are for cells at a stationary phase where available.  4	
Cell type Membrane lipids  
 CHL PC PE PS SM PI 
Synaptic vesicle [87] 29% 26% 30%* 9% 5% 1% 
CHO cells [88, 89]  26%# 25% 36% 5% 5% 2% 
HEK cells [89, 90] 19%  28% 37% 5% 6% 4% 
Xenopus oocytes [91, 92] 39%#  40% 11% 1% 3% 6% 
Abbreviations: CHL-cholesterol, PC-phosphatidylcholine, PE-phosphatidylethanolamine, PS-
phosphatidylserine, SM-sphingomyelin, PI-phosphatidylinositol, PL = phospholipid.  
# Mole percent. 
* The content of PE given as sum of 1-ester (17%) and 1-ether (13%) content. 
 5	
 6	
  7	
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Figures: 1	
 2	
Figure 1. Architecture of voltage-gated ion channels (VGICs). A) Schematic image of the six 3	
transmembrane helices (S1-S6) of each of the four domains (DI-DIV) of a VGIC. The linkers 4	
between the helices are dotted as they vary significantly in length depending type of VGIC and 5	
the interdomain linkers are absent in tetrameric channels. The voltage sensing domain (VSD) 6	
and the pore domain (PD) of the first domain are annotated. The inactivation (IFM) particle 7	
of NaVs in the DIII-DIV linker is depicted as a ball. The six helices of each of the four domains 8	
come together to form the functional channel. B) Top view a cartoon model of a recently 9	
described [20] mammalian voltage gated sodium channel (NaV1.4). The four domains are 10	
annotated and the four helices making up the VSD of domain I are also annotated. The ion-11	
conducting pore is at the hollow centre of the channel. C) Side view of the channel shown in 12	
B, where the large extracellular loops of the channel are evident. The approximate position of 13	
the lipid bilayer is indicated by the dotted lines. The ion-conduction path is indicated by the 14	
dotted arrow.  15	
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Figure 2. Figure showing the conserved amino acids in the S1-S4 helices of the voltage sensing 2	
domain (VSD) of voltage-gated ion channels (VGICs). The S3-S4 loop is missing in the PDB 3	
structure used - the missing linker is indicated by a dotted line [20].	The sidechains of the 4	
positively charged "gating" residues (arginines and lysines) on S4 are shown. The sidechains 5	
of conserved residues on S2 and S3 are also shown, which include the counter-charged (acidic) 6	
residues on S2/S3 and the hydrophobic plug (phenyl alanine) on S2. Movement of the S4 helix, 7	
in response to changes in membrane voltage, is thought to open and close the pore domain. 8	
  9	
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 1	
Figure 3. Schematic of a simplified model of the gating cycle in voltage gated sodium channels 2	
(NaVs). Only voltage sensing domains (VSDs) of domains II and IV are shown. The ‘up’ and 3	
‘down’ states are indicated by movements of the gating charges in the VSD (cylinder 4	
containing four ‘+’ symbols) with relation to the lipid bilayer. The fast inactivation of the 5	
channel by the inactivation (IFM) particle (cyan ball below the pore) is also shown. The 6	
binding site of venom peptides that can inhibit the channel are indicated with arrows, in the 7	
state that they would lead to inhibition of ion conduction. Upon membrane depolarisation, 8	
movement of the gating charges of the VSD open the inner gate of the pore domain and the 9	
channel transitions from the resting state (top left) to the open state (top right). The movement 10	
of the DIV gating charges lead to channel inactivation (bottom right), where the inner gate is 11	
open but occluded by the IFM particle. Upon repolarisation the gating charges move towards 12	
the intracellular side of the membrane and the inner gate closes and the channel is found in a 13	
closed inactivated (or deactivated) state (bottom left). Movement of the inactivation particle 14	
then returns the channel to the resting state.  15	
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 1	
Figure 4. Schematic description of the how gating modifier peptides bind to voltage-gated ion 2	
channels. The peptide in solution (Lf) first associates with the membrane (Lm), increasing its 3	
concentration near the receptor, prior to receptor binding (Lr).  4	
  5	
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 1	
Figure 5. Chemical structures of A) common phosphoglycerides, B) a ceramide and 2	
sphingomyelin and C) cholesterol. 3	
  4	
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 2	
Figure 6. The structural formula of 2,3-di-O-sesterpanyl-sn-glycerol-1-phospho-myo-inositol (C 25,25 3	
-archetidylinositol) (top: AI) and 2,3-di-O-sesterpanyl-sn-glycerol-1-phospho-1'-(2'O-α-D-glucosyl)-4	
myo-inositol (C 25,25 -archetidyl (glucosyl) inositol) (bottom: AGI). The C25 lipid chain, methyl 5	
branch and ether bonds are annotated. AGI and AI were the only two major lipids, accounting for 91 6	
mol% and 9 mol% of total polar lipids, of Aeropyrum pernix respectively [93, 94]. 7	
 8	
